Clinical Trials - August 9, 2021
First patient enrolled in Ultimovacs trial
Ultimovacs has announced that the first patient has been enrolled in FOCUS. FOCUS is an investigator-led Phase II randomized clinical trial in head-and-neck cancer of the company’s telomerase cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab. “Initiation of recruitment in FOCUS adds further momentum to the expanding clinical program of our lead cancer […]
Clinical Trials - May 24, 2021
New promising findings about Ultimovacs’ cancer vaccine
Ultimovacs has announced that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate (ORR) in metastatic malignant melanoma. All patients have been observed for at least 18 months and median observation time is 21 months. “Further strengthen the foundation for our broad Phase II clinical program […]
Clinical Trials - February 18, 2021
First patient treated in Ultimovacs TENDU study
Ultimovacs has announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the company’s Tetanus-Epitope Targeting (TET)-platform. The platform allows for the production of multiple therapeutic cancer vaccines that can be used to strengthen and increase T cell responses to cancer cells by targeting antigens […]
Clinical Trials - January 14, 2021
Ultimovacs announces Phase II collaboration study in ovarian cancer
Ultimovacs will participate in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups (ENGOT) and AstraZeneca. The collaborators will conduct a randomized Phase II clinical trial to evaluate Ultimovacs’ universal cancer vaccine, UV1, in combination with AstraZeneca’s durvalumab […]
Clinical Trials - December 30, 2020
Ultimovacs initiates Phase II trial
Ultimovacs has announced the initiation of FOCUS, a Phase II randomized clinical trial that will evaluate the company’s universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab. The trial will be conducted at 10 sites across Germany and led […]
Careers article - November 16, 2020
Hey there Carlos de Sousa, new CEO of Ultimovacs
In June this year, Carlos de Sousa commenced his role as Chief Executive Officer of Norwegian Ultimovacs, a pharmaceutical company developing novel immunotherapies against cancer. Congratulations on your new position! What made you say yes, or apply for the job? “Ultimovacs presented a unique opportunity with its UV1 universal vaccine approach in oncology and it […]
